Annovis Bio Prices $21 Million Public Offering to Fund Buntanetap Clinical Development

Annovis Bio entered into an underwriting agreement with Canaccord Genuity for a public offering expected to generate approximately $21.0 million in gross proceeds. The offering includes 19 million common shares, pre-funded warrants for up to 2 million shares in lieu of common stock for certain inve…